pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4259 |
Genomic Coordinates | chr1: 159899979 - 159900079 |
Description | Homo sapiens miR-4259 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4259 | |||||||||||||||||||||
Sequence | 70| CAGUUGGGUCUAGGGGUCAGGA |91 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | SOLiD | |||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SRCAP | ||||||||||||||||||||
Synonyms | DOMO1, EAF1, FLHS, SWR1 | ||||||||||||||||||||
Description | Snf2 related CREBBP activator protein | ||||||||||||||||||||
Transcript | NM_006662 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SRCAP | |||||||||||||||||||||
3'UTR of SRCAP (miRNA target sites are highlighted) |
>SRCAP|NM_006662|3'UTR 1 GTGGGCTGCCCCTCCACCTAGGCTTTCCACCGTGGCCACTCCCTCCATGACCAGGCCTGACTCTGTTAACCACTACTTGA 81 AGTCTTGAGGGGGAAAGCCTCCAGGGAGACATAGGGGCCTTCTCCCTTCTTCCCACCAAAGTAGGGGGTAGGCAACTGGT 161 TGTCATGGAAATGGGGATCATCACAGTCCCCTTCCCCTTCACCCCACGTGGCTGGGCAGTGTTAAGGGTGGCAAGATAGT 241 CTCTGTCCCCACCCCCTTGTACTTGATTCCCCAGCTGTCTTTCACACAGCCCCCCACCCTTAGGGGAAGGGGGAGGGGCT 321 TCTCTACAATGAGGTTTTTTTCTTTTTTTTTTTTTTTTAAGAAGAAAAAATAATAAACTTAGTTTCTGTATGAGCAAAAA 401 AAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | MCF7 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000396842.2 | 3UTR | GCCUCUCUCUCUUUCUCUCCUCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
40 hsa-miR-4259 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT074403 | TNRC6A | trinucleotide repeat containing 6A | 2 | 2 | ||||||||
MIRT082380 | HNRNPUL1 | heterogeneous nuclear ribonucleoprotein U like 1 | 2 | 6 | ||||||||
MIRT224489 | NDRG1 | N-myc downstream regulated 1 | 2 | 2 | ||||||||
MIRT227807 | GTF3C4 | general transcription factor IIIC subunit 4 | 2 | 2 | ||||||||
MIRT293253 | DR1 | down-regulator of transcription 1 | 2 | 2 | ||||||||
MIRT455060 | MEN1 | menin 1 | 2 | 2 | ||||||||
MIRT459206 | RCE1 | Ras converting CAAX endopeptidase 1 | 2 | 2 | ||||||||
MIRT464866 | UBB | ubiquitin B | 2 | 8 | ||||||||
MIRT464897 | UBALD1 | UBA like domain containing 1 | 2 | 2 | ||||||||
MIRT467210 | SPRY4 | sprouty RTK signaling antagonist 4 | 2 | 2 | ||||||||
MIRT467749 | SLC36A1 | solute carrier family 36 member 1 | 2 | 2 | ||||||||
MIRT470565 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT473523 | MAX | MYC associated factor X | 2 | 2 | ||||||||
MIRT474955 | KCTD10 | potassium channel tetramerization domain containing 10 | 2 | 4 | ||||||||
MIRT478575 | CTNND1 | catenin delta 1 | 2 | 2 | ||||||||
MIRT479952 | CBX4 | chromobox 4 | 2 | 6 | ||||||||
MIRT486151 | SIX5 | SIX homeobox 5 | 2 | 6 | ||||||||
MIRT488836 | MRRF | mitochondrial ribosome recycling factor | 2 | 2 | ||||||||
MIRT489466 | MSC | musculin | 2 | 2 | ||||||||
MIRT498922 | SRCAP | Snf2 related CREBBP activator protein | 2 | 2 | ||||||||
MIRT501166 | SLC10A7 | solute carrier family 10 member 7 | 2 | 6 | ||||||||
MIRT504195 | FAM127B | retrotransposon Gag like 8A | 2 | 2 | ||||||||
MIRT507342 | FAM168A | family with sequence similarity 168 member A | 2 | 2 | ||||||||
MIRT512629 | GPX1 | glutathione peroxidase 1 | 2 | 4 | ||||||||
MIRT514365 | UBBP4 | ubiquitin B pseudogene 4 | 2 | 6 | ||||||||
MIRT523321 | H3F3B | H3 histone family member 3B | 2 | 2 | ||||||||
MIRT529793 | AP4S1 | adaptor related protein complex 4 sigma 1 subunit | 2 | 2 | ||||||||
MIRT544301 | TSPYL1 | TSPY like 1 | 2 | 2 | ||||||||
MIRT552985 | VAT1 | vesicle amine transport 1 | 2 | 2 | ||||||||
MIRT562785 | LIMA1 | LIM domain and actin binding 1 | 2 | 2 | ||||||||
MIRT653090 | SSR3 | signal sequence receptor subunit 3 | 2 | 2 | ||||||||
MIRT661985 | DSN1 | DSN1 homolog, MIS12 kinetochore complex component | 2 | 4 | ||||||||
MIRT666982 | PHAX | phosphorylated adaptor for RNA export | 2 | 2 | ||||||||
MIRT683255 | WFDC6 | WAP four-disulfide core domain 6 | 2 | 2 | ||||||||
MIRT684051 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT686137 | B4GALT7 | beta-1,4-galactosyltransferase 7 | 2 | 2 | ||||||||
MIRT688435 | DNAL1 | dynein axonemal light chain 1 | 2 | 2 | ||||||||
MIRT698391 | TMED2 | transmembrane p24 trafficking protein 2 | 2 | 2 | ||||||||
MIRT698819 | STK38 | serine/threonine kinase 38 | 2 | 2 | ||||||||
MIRT715754 | HSD11B1L | hydroxysteroid 11-beta dehydrogenase 1 like | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|